This brief report assesses the efficacy of pembrolizumab, an inhibitor of programmed cell death 1 protein and its ligands, in a patient and in biopsy specimens of a series of patients with locally advanced cutaneous squamous cell carcinoma.
http://ift.tt/2mPeirh
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου